Medicines A–Z
A
| Status | Drug name | NICE TAs | Comments |
|---|---|---|---|
 |
Albumin solution | ||
|
Alemtuzumab concentrate for infusion | Hospital use only |
|
 |
Alendronic acid 70mg effervescent tablets (Binosto®) | Third line option in individuals who have not tolerated first line alendronate tablets and second line risedronate tablets and in whom a bone-sparing agent is still considered clinically necessary |
|
|
Alendronic acid tablets | ||
 |
Alfacalcidol (One-Alpha) | ||
|
Alfacalcidol injection | ||
|
Alfentanil injection | ||
|
Alfentanil intensive care® | High strength - Pallative care team recommendation during end of life care only |
|
 |
Alfentanil nasal spray (unlicensed) | ||
|
Alfuzosin M/R tablets |
Drug status key
Formulary drugs are allocated a traffic light status. This provides guidance on where clinical and prescribing responsibilities lie in regard to the initiation and maintenance of prescribing.
Grey
Positive NICE TA and/or awaiting local clarification on place in therapy. Please contact your medicines optimisation team for more information.
Red
Initiation and maintenance of prescribing by specialists only.
Amber
Initiation and maintenance of prescribing by specialists and transfer to primary care prescribing when appropriate, or in primary care following a specialists recommendation. Prior to initiation some medicines may require committee agreement or a framework to support safe transfer and maintenance.
Green
Initiation and maintenance of prescribing by specialists, GPs and other qualified clinicians.
Blue
Under review at University Hospitals Birmingham NHS Foundation Trust.
